LATEX AEROALLERGEN EMPLOYING A HOOD EXPOSURE CHAMBER

$0M01FY2000RRNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Paper 38816203 Paper 38741246 Paper 38204926 Paper 37978826 Paper 37226675 Paper 36933679 Paper 36515151 Paper 36280384 Paper 35562076 Paper 35453142 Paper 35019976 Paper 34753805 Paper 34637524 Paper 34559201 Paper 34558809 Paper 34029510 Paper 33707304 Paper 33627633 Paper 33597215 Paper 33178459 Paper 33168654 Paper 32845968 Paper 32841523 Paper 32388179 Paper 32134326 Paper 32128240 Paper 32085906 Paper 31898874 Paper 31338998 Paper 31131339 Paper 31028280 Paper 30900413 Paper 30421851 Paper 30348535 Paper 30053592 Paper 29545462 Paper 29086498 Paper 29053861 Paper 28940967 Paper 28678345 Paper 28340012 Paper 28257609 Paper 28068834 Paper 27595918 Paper 27471785 Paper 27465756 Paper 27367781 Paper 27271190 Paper 27114389 Paper 27076579 Paper 27028282 Paper 26856247 Paper 26833676 Paper 26761271 Paper 26578543 Paper 26504148 Paper 26489030 Paper 26487792 Paper 26474407 Paper 26420863 Paper 26386801 Paper 26322147 Paper 26203972 Paper 26164807 Paper 26025128 Paper 25860338 Paper 25707379 Paper 25666468 Paper 25573655 Paper 25504899 Paper 25155859 Paper 25127483 Paper 25115882 Paper 25048381 Paper 24986062 Paper 24901704 Paper 24892144 Paper 24855155 Paper 24853636 Paper 24828660 Paper 24771618 Paper 24699409 Paper 24533998 Paper 24518040 Paper 24436062 Paper 24307184 Paper 24286380 Paper 24174392 Paper 24123128 Paper 24081232 Paper 24016822 Paper 23996977 Paper 23958264 Paper 23899896 Paper 23804576 Paper 23796131 Paper 23767996 Paper 23757437 Paper 23716070 Paper 23683464

Abstract

The hooded exposure chamber technique is designed to safely expose latex allergic patients to small amounts of inhaled latex particles to determine their latex sensitivity. Latex allergic patients are defined as those positive to latex skin testing. Upper and lower airway responses are monitored during the 2-3 hour procedure. The protocol objectives are to validate the hooded exposure chamber as a clinical marker of latex allergy and its acceptability as the primary endpoint in a planned clinical trial of latex immunotherapy.

View original record on NIH RePORTER →